

News
Categories
Sign up
Featured Posts


Archive


- Mar 12
Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank

- Mar 10
Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update

- Mar 9
Treatment of 1st two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

- Mar 5
Receipt of Increased Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval

- Mar 1
Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases


- Dec 14, 2022
Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event


- Nov 23, 2022
Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update


- Nov 10, 2022
Alpha Tau to Present at Upcoming November Investor Conferences


- Oct 24, 2022
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society


- Sep 11, 2022
Acceptance in Major Peer-Reviewed Journals of two Landmark Pre-Clinical Studies